Loading
A phase 3 trial of Imatinib in chronic myeloid leukaemia, run by Il-Yang Pharm. Co., Ltd., active and no longer recruiting.
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) is a phase 3 interventional study registered as NCT03722420 by Il-Yang Pharm. Co., Ltd., with 238 participants enrolled, started 2018-12-28 and due to reach its primary completion in 2023-03-03. Interventions recorded: Radotinib and Imatinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Radotinib, Il-Yang Pharmaceutical, Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Imatinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/